HRP20050198A2 - Piperidin-piridazoni i ftalazoni kao inhibitori pde4 - Google Patents

Piperidin-piridazoni i ftalazoni kao inhibitori pde4

Info

Publication number: HRP20050198A2
Authority: HR; Croatia
Prior art keywords: alkoxy; hydrogen; alkyl; integer; formula
Prior art date: 2002-08-10

Application number

HR20050198A

Other languages

English (en)

Croatian (hr)

Inventor

Hatzelmann Armin

Barsig Johannes

Marx Degenhard

Kley Hans-Peter

A.M. Christiaans Johannes

M.P.B. Menge Wiro

Geert Sterk Jan

Original Assignee

Altana Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-10

Filing date

2003-08-06

Publication date

2006-04-30

2003-08-06 Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag

2006-04-30 Publication of HRP20050198A2 publication Critical patent/HRP20050198A2/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)

HR20050198A 2002-08-10 2003-08-06 Piperidin-piridazoni i ftalazoni kao inhibitori pde4 HRP20050198A2 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02017977		2002-08-10
PCT/EP2003/008724 WO2004017974A1 (en)	2002-08-10	2003-08-06	Piperidine-pyridazones and phthalazones as pde4 inhibitors

Publications (1)

Publication Number	Publication Date
HRP20050198A2 true HRP20050198A2 (hr)	2006-04-30

Family

ID=31896827

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20050198A HRP20050198A2 (hr)	2002-08-10	2003-08-06	Piperidin-piridazoni i ftalazoni kao inhibitori pde4

Country Status (18)

Country	Link
US (2)	US20060094710A1 (pl)
EP (2)	EP1537100B1 (pl)
JP (2)	JP2005538140A (pl)
KR (1)	KR101131684B1 (pl)
CN (1)	CN1671695A (pl)
AT (1)	ATE360627T1 (pl)
AU (2)	AU2003260376A1 (pl)
BR (1)	BR0313330A (pl)
CA (2)	CA2494634A1 (pl)
DE (1)	DE60313472T2 (pl)
ES (1)	ES2286491T3 (pl)
HR (1)	HRP20050198A2 (pl)
IL (1)	IL166271A (pl)
IS (2)	IS2416B (pl)
MX (1)	MXPA05001354A (pl)
PL (2)	PL214701B1 (pl)
RS (1)	RS51445B (pl)
WO (2)	WO2004017974A1 (pl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20030636B1 (en)	2001-02-15	2012-05-31	Nycomed Gmbh	Phthalayinone-piperidino-derivatives as pde4 inhibitors
MY140561A (en)	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
DK1606261T3 (da)	2003-03-10	2010-01-18	Nycomed Gmbh	Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US20080227790A1 (en) *	2004-02-04	2008-09-18	Altana Pharma Ag	Pyridazinone Derivatives and their Use as Pde4 Inhibitors
AU2005210042B2 (en) *	2004-02-04	2011-04-21	Takeda Gmbh	2-(piperidin-4-yl) -4, 5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
US20070254928A1 (en) *	2004-05-10	2007-11-01	Altana Pharma Ag	Use of Roflumilast for the Prophylaxis or Treatment of Emphysema
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
AU2006224619B2 (en)	2005-03-16	2012-06-07	Takeda Gmbh	Taste masked dosage form containing roflumilast
GB0507577D0 (en)	2005-04-14	2005-05-18	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
US7910708B2 (en)	2005-10-21	2011-03-22	Novartis Ag	Anti-IL13 human antibodies
GB0526244D0 (en)	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
ATE549337T1 (de)	2006-04-21	2012-03-15	Novartis Ag	Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
KR20090073121A (ko)	2006-09-29	2009-07-02	노파르티스 아게	Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
KR20090075714A (ko)	2006-10-30	2009-07-08	노파르티스 아게	소염제로서의 헤테로시클릭 화합물
RS51644B (sr)	2007-01-10	2011-10-31	Irm Llc.	Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
WO2008127898A1 (en) *	2007-04-11	2008-10-23	Martinez Rodolfo A	Single carbon precursor synthons
KR20100005730A (ko)	2007-05-07	2010-01-15	노파르티스 아게	유기 화합물
SI2148876T1 (sl)	2007-05-16	2012-01-31	Nycomed Gmbh	Pirazolonski derivati kot PDE4 inhibitorji
EA017919B1 (ru)	2007-12-10	2013-04-30	Новартис Аг	Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
EP2231642B1 (en)	2008-01-11	2013-10-23	Novartis AG	Pyrimidines as kinase inhibitors
KR20110040818A (ko)	2008-06-10	2011-04-20	노파르티스 아게	상피 나트륨 채널 차단제로서의 피라진 유도체
AR074318A1 (es) *	2008-11-14	2011-01-05	Nycomed Gmbh	Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
PL2391366T3 (pl)	2009-01-29	2013-04-30	Novartis Ag	Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru)	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
MY162604A (en)	2009-08-17	2017-06-30	Intellikine Llc	Heterocyclic compounds and uses thereof
MX2012002179A (es)	2009-08-20	2012-03-16	Novartis Ag	Compuestos heterociclicos de oxima.
EP2813227A1 (en)	2009-10-22	2014-12-17	Vertex Pharmaceuticals Incorporated	Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
US8637516B2 (en)	2010-09-09	2014-01-28	Irm Llc	Compounds and compositions as TRK inhibitors
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
JP2014505088A (ja)	2011-02-10	2014-02-27	ノバルティスアーゲー	Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en)	2011-02-23	2016-08-10	Intellikine, LLC	Heterocyclic compounds and uses thereof
AU2012220572A1 (en)	2011-02-25	2013-08-29	Irm Llc	Compounds and compositions as trk inhibitors
EP2721030B1 (en) *	2011-06-17	2015-12-16	Takeda GmbH	Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
US8883819B2 (en)	2011-09-01	2014-11-11	Irm Llc	Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es)	2011-09-15	2013-04-30	Novartis Ag	Compuestos de triazolopiridina
WO2013038386A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine/pyrazine amide derivatives
WO2013038373A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038378A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
ES2882807T3 (es)	2011-09-16	2021-12-02	Novartis Ag	Heterociclil carboxamidas N-sustituidas
US20130209543A1 (en)	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en)	2012-03-19	2014-08-19	Novartis Ag	Crystalline form
CN110507654A (zh)	2012-04-03	2019-11-29	诺华有限公司	有酪氨酸激酶抑制剂的组合产品和其应用
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en)	2013-03-15	2016-08-10	Intellikine Llc	COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en)	2013-12-03	2015-06-11	Novartis Ag	Combination of mdm2 inhibitor and braf inhibitor and their use
US10112926B2 (en)	2014-04-24	2018-10-30	Novartis Ag	Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
PL3134395T3 (pl)	2014-04-24	2018-07-31	Novartis Ag	Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
EP3134397A1 (en)	2014-04-24	2017-03-01	Novartis AG	Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
KR20170036037A (ko)	2014-07-31	2017-03-31	노파르티스 아게	조합 요법
EP3980121A1 (en)	2019-06-10	2022-04-13	Novartis AG	Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN113105411B (zh) *	2019-06-28	2023-03-17	深圳市三启药物开发有限公司	腙酰胺类衍生物及药物组合物
PH12022550468A1 (en)	2019-08-28	2023-03-06	Novartis Ag	Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0553174B1 (de)	1990-10-16	1998-07-08	Byk Gulden Lomberg Chemische Fabrik Gmbh	Arylpyridazinone
US5716954A (en) *	1991-10-09	1998-02-10	Syntex U.S.A. Inc.	Benzopyridazinone and pyridopyridazinone compounds
JP3245165B2 (ja)	1991-10-09	2002-01-07	シンテックス（ユー・エス・エイ）・インコーポレイテッド	ピリドピリダジノンおよびピリダジンチオン化合物
BR9307570A (pt)	1992-12-02	1999-05-25	Pfizer	Diéteres de catecol como inibidores seletivos de pdeiv
DE19533975A1 (de)	1995-09-14	1997-03-20	Merck Patent Gmbh	Arylalkyl-diazinone
US5658940A (en) *	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
ES2193508T3 (es) *	1997-01-15	2003-11-01	Altana Pharma Ag	Ftalizinonas.
AU1760399A (en)	1997-12-15	1999-07-05	Byk Gulden Lomberg Chemische Fabrik Gmbh	New phthalazinones
ATE258930T1 (de)	1997-12-15	2004-02-15	Altana Pharma Ag	Dihydrobenzifurane
DK1070056T3 (da)	1998-03-14	2004-11-08	Altana Pharma Ag	Phthalazinon-PDE III/IV-inhibitorer
WO2001019818A1 (en)	1999-09-14	2001-03-22	Byk Gulden Lomberg Chemische Fabrik Gmbh	Phthalazinone derivatives as pd3/4 inhibitors
HUP0203487A2 (hu)	1999-10-25	2003-02-28	Byk Gulden Lomberg Chemische Fabrik Gmbh	Tetrahidrotiopirán-ftalazinon-származékok, mint PDE4-inhibitorok és ezeket tartalmazó gyógyszerkészítmények
EP1228046B1 (en)	1999-10-25	2007-09-26	Nycomed GmbH	Phthalazinone derivatives as pde 4 inhibitors
CZ20023997A3 (cs)	2000-06-05	2003-05-14	Altana Pharma Ag	Pyridazinonové deriváty
HRP20030636B1 (en) *	2001-02-15	2012-05-31	Nycomed Gmbh	Phthalayinone-piperidino-derivatives as pde4 inhibitors
DE10112864A1 (de) *	2001-03-16	2002-09-19	Alstom Switzerland Ltd	Verfahren zum Zünden einer thermischen Turbomaschine
EE200300514A (et) *	2001-04-25	2004-02-16	Altana Pharma Ag	Ftalasinoonid, nende kasutamine hingamisteede haigusnähte leevendavate ravimite valmistamiseks ningneid sisaldavad ravimid
JP4021329B2 (ja)	2001-04-25	2007-12-12	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	ピペラジノ誘導体およびｐｄｅ４阻害剤としてのその使用

2003
- 2003-08-06 JP JP2004530096A patent/JP2005538140A/ja active Pending
- 2003-08-06 AU AU2003260376A patent/AU2003260376A1/en not_active Abandoned
- 2003-08-06 HR HR20050198A patent/HRP20050198A2/hr not_active Application Discontinuation
- 2003-08-06 ES ES03792257T patent/ES2286491T3/es not_active Expired - Lifetime
- 2003-08-06 US US10/523,111 patent/US20060094710A1/en not_active Abandoned
- 2003-08-06 JP JP2004530086A patent/JP4555684B2/ja not_active Expired - Fee Related
- 2003-08-06 EP EP03792257A patent/EP1537100B1/en not_active Expired - Lifetime
- 2003-08-06 BR BR0313330-3A patent/BR0313330A/pt not_active Application Discontinuation
- 2003-08-06 CA CA002494634A patent/CA2494634A1/en not_active Abandoned
- 2003-08-06 MX MXPA05001354A patent/MXPA05001354A/es active IP Right Grant
- 2003-08-06 PL PL373645A patent/PL214701B1/pl unknown
- 2003-08-06 DE DE60313472T patent/DE60313472T2/de not_active Expired - Lifetime
- 2003-08-06 CN CNA038185202A patent/CN1671695A/zh active Pending
- 2003-08-06 CA CA2494613A patent/CA2494613C/en not_active Expired - Fee Related
- 2003-08-06 EP EP03792267A patent/EP1556049A1/en not_active Withdrawn
- 2003-08-06 US US10/523,412 patent/US7220746B2/en not_active Expired - Fee Related
- 2003-08-06 PL PL03372926A patent/PL372926A1/pl not_active Application Discontinuation
- 2003-08-06 AT AT03792257T patent/ATE360627T1/de active
- 2003-08-06 WO PCT/EP2003/008724 patent/WO2004017974A1/en not_active Ceased
- 2003-08-06 KR KR1020057001920A patent/KR101131684B1/ko not_active Expired - Fee Related
- 2003-08-06 RS YUP-2005/0112A patent/RS51445B/sr unknown
- 2003-08-06 AU AU2003258576A patent/AU2003258576B2/en not_active Ceased
- 2003-08-06 WO PCT/EP2003/008675 patent/WO2004018457A1/en not_active Ceased
2005
- 2005-01-13 IL IL166271A patent/IL166271A/en not_active IP Right Cessation
- 2005-02-28 IS IS7718A patent/IS2416B/is unknown
- 2005-03-01 IS IS7721A patent/IS7721A/is unknown

Also Published As

Publication number	Publication date
AU2003258576B2 (en)	2009-07-30
DE60313472D1 (de)	2007-06-06
IS2416B (is)	2008-10-15
CA2494634A1 (en)	2004-03-04
US20060094710A1 (en)	2006-05-04
RS20050112A (sr)	2007-06-04
JP2005538140A (ja)	2005-12-15
BR0313330A (pt)	2005-06-14
ATE360627T1 (de)	2007-05-15
CN1671695A (zh)	2005-09-21
WO2004018457A8 (en)	2004-05-06
IL166271A (en)	2011-02-28
WO2004017974A1 (en)	2004-03-04
PL214701B1 (pl)	2013-09-30
KR20050026568A (ko)	2005-03-15
RS51445B (sr)	2011-04-30
EP1556049A1 (en)	2005-07-27
IS7718A (is)	2005-02-28
WO2004018457A1 (en)	2004-03-04
CA2494613C (en)	2011-06-28
US20060160813A1 (en)	2006-07-20
ES2286491T3 (es)	2007-12-01
US7220746B2 (en)	2007-05-22
EP1537100A1 (en)	2005-06-08
AU2003260376A1 (en)	2004-03-11
PL372926A1 (pl)	2005-08-08
IL166271A0 (en)	2006-01-15
IS7721A (is)	2005-03-01
CA2494613A1 (en)	2004-03-04
MXPA05001354A (es)	2005-04-28
EP1537100B1 (en)	2007-04-25
JP4555684B2 (ja)	2010-10-06
JP2006500370A (ja)	2006-01-05
PL373645A1 (pl)	2005-09-05
KR101131684B1 (ko)	2012-03-28
AU2003258576A1 (en)	2004-03-11
DE60313472T2 (de)	2008-01-24

Legal Events

Date

Code

Title

Description

2005-07-28

ODRP

Renewal fee for the maintenance of a patent

Payment date: 20050728

Year of fee payment: 3